Reduction in Physician Reimbursement and Use of Hormone Therapy in Prostate Cancer
Citations
26 citations
23 citations
23 citations
Cites background from "Reduction in Physician Reimbursemen..."
...Among them, the Medicare Modernization Act of 2003 changed the reimbursement landscape substantially for cancer care, especially for chemotherapy, which is a dominant focus of investigation in NCI clinical trials [10,11]....
[...]
18 citations
15 citations
Cites background from "Reduction in Physician Reimbursemen..."
...For example, two recent studies of the impact of reducing Medicare’s reimbursement rate for primary androgen deprivation therapy in the treatment of prostate cancer found significant reductions primarily among cases where its use was deemed inappropriate (Shahinian et al. 2010; Elliott et al. 2010)....
[...]
References
39,961 citations
"Reduction in Physician Reimbursemen..." refers methods in this paper
...Comorbidity was classified using a modification of the Charlson comorbidity index for use with Medicare data (19,20)....
[...]
3,500 citations
1,692 citations
"Reduction in Physician Reimbursemen..." refers background in this paper
...AST, delivered as a depot injection of luteinizing hormone– releasing hormone, is indicated for management of prostate cancer in two clinical situations, as palliative therapy in metastatic prostate cancer (6) or in combination with external beam radiotherapy in the treatment of locally advanced prostate cancer (7), for which it has been shown to improve survival....
[...]
1,602 citations
"Reduction in Physician Reimbursemen..." refers methods in this paper
...Comorbidity was classified using a modification of the Charlson comorbidity index for use with Medicare data (19,20)....
[...]
1,505 citations